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A B S T R A C T
Proteus mirabilis is a major cause of urinary tract infection (UTI) in humans and companion animals. This study
aimed to evaluate the antimicrobial resistance, virulence and clonal relatedness of P. mirabilis isolated from dogs,
cats and humans with UTI.
P. mirabilis isolated from companion animals (N= 107) and humans (N=76) with UTI were compared by
PFGE analysis after overnight NotI macro-restriction using Dice/UPGMA with a 1.5% tolerance. Strains were
characterized for antimicrobial resistance by disk diffusion. Twenty-four resistance genes and four virulence
genes were screened by PCR.
Thirty-nine clusters (similarity> 80%) and 73 single pulse-types were detected. Nine clusters included P.
mirabilis isolated from community and hospital patients, including strains with 100% similarity. A high number
of clusters (43.6%, n=17/39) included strains from companion animals and humans. Similarity between some
companion animal and human strains varied between 80–100%. One strain from a dog was 100% similar to one
human community-acquired P. mirabilis. One P. mirabilis from a cat was found to be 94.7% and 92.4% similar to
community and hospital patient strains, respectively. P. mirabilis CMY-2-producers did not cluster all together.
Nevertheless, cluster C36 included five P. mirabilis from companion animals (similarity 85.8%–95.7%), of which,
four (80%) were multidrug-resistant CMY-2-producers.
This study shows that companion animals and humans become infected with closely related P. mirabilis
strains. The high number of clusters containing companion animals and human strains points to the zoonotic
nature of P. mirabilis. These results underline the potential role of companion animals as reservoirs and in the
dissemination of uropathogenic P. mirabilis to humans and vice versa.
1. Introduction
Proteus mirabilis are known to cause community-acquired urinary
tract infections (UTI) in humans and are important agents of nosoco-
mial UTIs (Armbruster and Mobley, 2012; Costa et al., 2018). After E.
coli, which is the main cause of UTI, P. mirabilis is the second most
common Enterobacteriacea isolated in companion animals with UTI
(Moyaert et al., 2017). The increasing antimicrobial resistance trends in
bacteria isolated from companion animals creates concerns regarding
the role of companion animals as reservoirs of resistant bacteria to
humans (Marques et al., 2017; Pomba et al., 2017). CMY-2-producing P.
mirabilis, which are resistant to third-generation cephalosporins and
frequently multidrug-resistant (MDR), are increasingly being reported
in companion animals in Portugal (Marques et al., 2017). Since com-
panion animals with UTI caused by P. mirabilis have high loads of
bacteria in urine and faeces (Gaastra et al., 1996), the risk of dis-
semination of uropathogenic P. mirabilis, including potential resistant
strains, into the owners living environment may be an important ha-
zard.
Little is known about the clonal relatedness between human and
companion animal uropathogenic P. mirabilis. Yet, this information is
relevant to understand the role of companion animals and human as
reservoirs of P. mirabilis. Only a limited number of European studies on
resistance monitoring of UTI in companion animals are available
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(Marques et al., 2017; Moyaert et al., 2017). Furthermore, only early
studies report the frequency of virulence factors among P. mirabilis from
companion animals (Bijlsma et al., 1995; Gaastra et al., 1996).
The main goal of this study was to determine the clonal relatedness
of P. mirabilis isolated from companion animals (dogs and cats) and
humans with UTI. Additionally, these uropathogenic P. mirabilis were
characterised for the presence of antimicrobial resistance and virulence
genes.
2. Material and methods
2.1. Bacteria isolates
This study included P. mirabilis isolated from humans with UTI
(N= 76) at a private clinical analysis laboratory (N=50) in 2014 and
between 2006–2015 from hospital microbiology laboratories (N= 26)
collecting samples from patients in the Lisbon area. The P. mirabilis
isolated at the human private laboratory were obtained from humans
with community-acquired UTI (CA-human). Samples from the hospital
laboratories were obtained from hospital patients with UTI (HA-
human) and were likely hospital-acquired. However, it was not possible
to ensure that these infections were nosocomial due to insufficient
patient data. Non-duplicate P. mirabilis strains from companion animals
with UTI (dogs N=94, cats N= 13) were obtained from 1999 to early
2015 at the Laboratory of Antimicrobial Resistance from the Veterinary
Teaching Hospital of the Faculty of Veterinary Medicine/University of
Lisbon and therefore all companion animals were also from the Lisbon
area.
Besides being collected from the same geographical region, there
were no direct epidemiological relations between the sampled humans
and companion animals. It was also not possible to obtain information
regarding the overall daily contact of the sampled humans and com-
panion animals with UTI. Moreover, data on prior antimicrobial use
was not available.
2.2. Bacteriological methods
P. mirabilis strains were isolated by standard quantitative urine
cultures and species identification was conducted by phenotypical tests
(API20E and VITEKII, BioMérieux, Marcy-l'Étoile, France) and con-
firmed by P. mirabilis species-specific PCR (Marques et al., 2017).
2.3. Susceptibility testing
Antimicrobial susceptibility testing was performed by disk diffusion
method according to CLSI guidelines (CLSI, 2018, 2017). Isolates were
tested for susceptibility against a total of twenty-six antimicrobials
(Oxoid, Hampshire, UK): ampicillin 10μg, amoxicillin/clavulanate
30μg, cefoxitin 30μg, cefotaxime 30μg, ceftazidime 30μg, cefovecin
30μg, piperacillin-tazobactam 110μg, cefepime 30μg, imipenem 10μg,
meropenem 10μg, aztreonam 30μg, ertapenem 10μg, nalidixic acid
30μg, ciprofloxacin 5μg, enrofloxacin 5μg, norfloxacin 10μg, levo-
floxacin 5μg, gentamicin 10μg, kanamycin 30μg, netilmicin 30μg, to-
bramycin 10μg, amikacin 30μg, chloramphenicol 30μg, florfenicol
30μg, fosfomycin 50μg and trimethoprim/sulfamethoxazole 25μg.
For cefovecin and enrofloxacin results interpretation, the veterinary
CLSI breakpoints were applied (CLSI, 2018). Florfenicol (a fluorinated
compound in use for bovine respiratory infections) was tested for epi-
demiological purposes only. Since there are no defined florfenicol
breakpoints for companion animals nor humans, interpretation dia-
meter limits were derived from the veterinary CLSI breakpoints for
swine infections (CLSI, 2018). The Societé Française de Microbiology
breakpoints were used for fosfomycin (SFM, 2010). Since gentamicin
breakpoints only vary between veterinary and human CLSI guidelines
by 1mm in the susceptible/intermediate categorisation (CLSI, 2017,
2018), human CLSI was used. The remaining antimicrobials were
interpreted according to human CLSI breakpoints (CLSI, 2017), since
breakpoints either are equal or are not determined in veterinary CLSI
standards.
Antimicrobial categories were used to characterize MDR
Enterobacteriacea (Magiorakos et al., 2012). P. mirabilis were con-
sidered as MDR when resistant to three or more antimicrobial cate-
gories.
2.4. Antimicrobial resistance determinants
Ampicillin resistant/intermediate isolates were tested for the pre-
sence of blaTEM, blaSHV and blaOXA-1 beta-lactamase genes by PCR
(Pomba et al., 2006). The presence of ESBL (blaCTX-M-type) and AmpC
(blaCMY-type, blaLAT-type, blaBIT-1, blaDHA-type, blaMOX-type, blaACT-type, blaFOX-
type and blaMIR-type) beta-lactamase genes among third-generation ce-
phalosporin resistant strains has been characterized elsewhere
(Marques et al., 2017).
Antimicrobial resistant/intermediate isolates were further screened
by PCR for the presence of antimicrobial resistance genes against
aminoglycosides [aphAI-IAB, aac(6′)-Ib and aac(3′)-IV] (Frana et al.,
2001; Sáenz et al., 2004; Robicsek et al., 2006a), phenicols (floR)
(Sáenz et al., 2004), fluoroquinolones (qnrA, qnrB, qnrC, qnrD and qnrS)
(Robicsek et al., 2006b; Cavaco et al., 2009; Wang et al., 2009) and
trimethoprim-sulfamethoxazole (sul1, sul2, sul3, dfrA12 and dfrIa [tar-
geting dfrA1, dfrA5, dfrA15, dfrA15b, dfrA16, dfrA16b]) (Sáenz et al.,
2004; Guerra et al., 2001; Maynard et al., 2003; Perreten and Boerlin,
2003).
2.5. Virulence genes
All P. mirabilis were screened by PCR for the presence of ucaA (ur-
othelial cell adhesion fimbriae [UCA/NAF]), mrpA (mannose-resistant
Proteus-like fimbriae [MR/P]) and pmfA (Proteus mirabilis fimbriae
[PMF]) fimbriae genes and for the presence of haemolysin HpmA/HpmB
codifying genes (Sosa et al., 2006; Cestari et al., 2013).
2.6. Population structure and data analysis
P. mirabilis were characterized by overnight restriction with NotI
(Thermo Scientific™, Lisbon, Portugal) and subsequent PFGE on a CHEF
DR II-apparatus (Biorad, Hercules, CA, USA). The restriction fragments
were resolved in a 1% agarose gel (agarose pulse-field grade, Nzytech -
Genes and Enzymes, Lisbon, Portugal) using the following previously
described block conditions: 1–30 s for 8 h followed by 30–70 s for 16 h
at 14 °C, 6 V/cm2 (Sabbuba et al., 2003).
P. mirabilis NotI restriction PFGE-pattern analysis was conducted
with the Bionumerics software, version 6.6, (Applied Maths from
BioMérieux, Marcy-l'Étoile, France) using Dice/ UPGMA clustering
method with a tolerance of 1.5% and a clustering cut-off of 80%.
The SAS statistical software package for Windows, version 9.3, (SAS
Institute Inc, Cary, North Carolina, USA) was used to perform statistical
analysis. Comparisons between groups were conducted by Fisher’s
Exact test, with an alpha value of 0.05.
3. Results
3.1. Antimicrobial resistance and antimicrobial resistance determinants
Considering beta-lactam non-susceptible strains (categorized as
antimicrobial resistant or intermediate isolates), P. mirabilis from
companion animals and CA-humans were frequently resistant only to
ampicillin (46.9%, N=15/32 and 86.7%, N=13/15, respectively)
while HA-human P. mirabilis were frequently resistant to ampicillin and
intermediate or resistant to amoxicillin/clavulanate (61.5%, N=8/13)
(Table 1).
Beta-lactam non-susceptible P. mirabilis strains frequently
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harboured blaTEM (88.3%) while blaOXA-1 and blaSHV were not detected
(Table 2). Third-generation cephalosporin-resistance was only present
in P. mirabilis from companion animals and was mostly linked to the
presence of the blaCMY-2 gene.
Resistance to fluoroquinolones was higher in isolates from HA-
human UTIs, followed by companion animal and CA-Human UTIs
(Table 1). Three main fluoroquinolone-non-susceptible phenotypes
were detected, namely non-susceptibility to nalidixic acid and enro-
floxacin with or without ciprofloxacin-non-susceptibility and non-sus-
ceptibility to all tested fluoroquinolones including norfloxacin and le-
vofloxacin. Interestingly, the non-susceptibility to nalidixic acid and
enrofloxacin phenotype was significantly more common in companion
animal P. mirabilis strains isolated prior to 2006 (75%, N=12/16,
P= 0.0003) while non-susceptibility to all fluoroquinolones became
Table 1







%R %I %R %I %R %I
Ampicillin 28.0% (n=30) 1.9% (n= 2) 30.0% (n=15) 0% (n=0) 50.0% (n= 13) 0% (n=0)
Amoxicillin/clavulanate 9.4% (n= 10) 5.6% (n= 6) 2.0% (n= 1) 2.0% (n= 1) 3.8% (n= 1) 26.9% (n=7)
Cefoxitin 9.4% (n= 10) 0% (n=0) 0% (n=0) 0% (n=0) 0% (n=0) 0% (n=0)
Cefotaxime 9.4% (n= 10) 0% (n=0) 0% (n=0) 0% (n=0) 0% (n=0) 0% (n=0)
Ceftazidime 5.6% (n= 6) 3.7% (n= 4) 0% (n=0) 0% (n=0) 0% (n=0) 0% (n=0)
Cefovecin 9.4% (n= 10) 0% (n=0) 0% (n=0) 0% (n=0) 0% (n=0) 0% (n=0)
Piperacillin-tazobactam 1.9% (n= 2) 0% (n=0) 0% (n=0) 0% (n=0) 0% (n=0) 0% (n=0)
Cefepime 0% (n=0) 5.6% (n= 6) 0% (n=0) 0% (n=0) 0% (n=0) 0% (n=0)
Imipenem 0% (n=0) 7.5% (n= 8) 0% (n=0) 2% (n=1) 0% (n=0) 0% (n=0)
Meropenem 0% (n=0) 0% (n=0) 0% (n=0) 0% (n=0) 0% (n=0) 0% (n=0)
Aztreonam 1.9% (n= 2) 0% (n=0) 0% (n=0) 0% (n=0) 0% (n=0) 0% (n=0)
Ertapenem 0% (n=0) 0% (n=0) 0% (n=0) 0% (n=0) 0% (n=0) 0% (n=0)
Nalidixic acid 26.2% (n=28) 4.7% (n= 5) 16.0% (n=8) 4.0% (n= 2) 42.3% (n= 11) 0% (n=0)
Ciprofloxacin 8.4% (n= 9) 5.6% (n= 6) 8.0% (n= 4) 2.0% (n= 1) 26.9% (n= 7) 3.8% (n= 1)
Enrofloxacin 26.2% (n=28) 1.9% (n= 2) 16.0% (n=8) 0% (n=0) 42.3% (n= 11) 0% (n=0)
Norfloxacin 5.6% (n= 6) 1.9% (n= 2) 6.0% (n= 3) 0% (n=0) 19.2% (n= 5) 3.8% (n= 1)
Levofloxacin 7.5% (n= 8) 0% (n=0) 8.0% (n= 4) 0% (n=0) 23.1% (n= 6) 0% (n=0)
Gentamicin 6.5% (n= 7) 2.8% (n= 3) 10.0% (n=5) 0% (n=0) 30.8% (n= 8) 0% (n=0)
Kanamycin 20.6% (n=22) 5.6% (n= 6) 12.0% (n=6) 2.0% (n= 1) 11.5% (n= 3) 0% (n=0)
Netilmicin 3.7% (n= 4) 2.8% (n= 3) 2.0% (n= 1) 0% (n=0) 7.7% (n= 2) 0% (n=0)
Tobramycin 5.6% (n= 6) 1.9% (n= 2) 4.0% (n= 2) 0% (n=0) 0% (n=0) 0% (n=0)
Amikacin 2.8% (n= 3) 0.9% (n= 1) 0% (n=0) 0% (n=0) 0% (n=0) 0% (n=0)
Trimethoprim/sulfamethoxazole 35.5% (n=38) 1.9% (n= 2) 26.0% (n=13) 0% (n=0) 38.5% (n= 10) 3.8% (n= 1)
Chloramphenicol 28.0% (n=30) 18.7% (n= 20) 20.0% (n=10) 8.0% (n= 4) 11.5% (n= 3) 11.5% (n=3)
Florfenicol 5.6% (n= 6) 10.3% (n= 11) 4.0% (n= 2) 2.0% (n= 1) 0% (n=0) 15.4% (n=4)
Fosfomycin 5.6% (n= 6) 0% (n=0) 2.0% (n= 1) 0% (n=0) 0% (n=0) 0% (n=0)
Legend: N, total sample number; %R, percentage of resistant isolates; %I percentage of intermediate isolates; n, number of isolates; HA-human, human hospital-
patient UTI; CA-human, human community-acquired UTI.
Table 2
Antimicrobial resistance genes detected in antimicrobial non-susceptible P. mirabilis strains.




























































































Legend: n, number of positive among tested isolates; HA-human, human hospital-patient UTI; CA-human, human community-acquired UTI; -, no strains were tested
since all strains were susceptible; a, P. mirabilis from companion animals were compared with P. mirabilis from humans (CA-human+HA-human) by Fisher’s Exact
test.
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significantly more frequent thereafter (44.4%, N=8/18, P= 0.0031)
(data not shown). Only qnrD was detected in P. mirabilis from compa-
nion animals and humans (Table 2).
Among aminoglycosides, kanamycin and gentamicin showed the
highest non-susceptibility frequencies (Table 1) and the aphAI-IAB was
the most common resistance gene detected (Table 2).
Both in companion animal and human P. mirabilis, resistance against
trimethoprim/sulfamethoxazole was high (26.0%–38.5%) (Table 1).
The frequency of sul1 was significantly lower in P. mirabilis from
companion animals when compared to strains from humans overall
(Table 2). However, when compared to strains from CA-human only, a
statistical significant difference was not detected (P= 0.1403). The
frequency of sul2 in P. mirabilis from CA-human was significantly higher
than in strains from HA-human (P=0.0470). Nonetheless, sul1 and
sul2 were detected in P. mirabilis from all patients while sul3 was only
detected in P. mirabilis from companion animals (Table 2). All tri-
methoprim/sulfamethoxazole non-susceptible P. mirabilis lacked dfrA12
and several strains were negative for sul1, sul2 and sul3 (companion
animal 37.5%, N=15/40; CA-human 15.4%, N=2/13; HA-human
18.2%, n=2/11). Overall, dfrIa was common in P. mirabilis from all
patients (Table 2).
Chloramphenicol-resistance was high, especially in companion an-
imal and CA-human P. mirabilis (Table 1). The floR gene was only de-
tected in P. mirabilis from companion animals (Table 2) and all were co-
resistant to chloramphenicol and florfenicol.
MDR P. mirabilis were more frequent among HA-human (42.3%,
N=11/26) strains, followed by companion animal (21.5%, N=23/
107) and CA-human (18%, N=9/50). However, most MDR P. mirabilis
were only resistant to three antimicrobial categories (HA-human,
30.8%, N=8/26; CA-human, 10%, N=5\50 and companion animals,
10.3%, N=11/107). P. mirabilis from human patients were resistant to
up to 5 antimicrobial categories while third-generation cephalosporin-
resistant P. mirabilis from companion animals were resistant to 5 up to 9
antimicrobial categories.
3.2. Virulence genes
All fimbriae genes (ucaA, pmfA and mrpA) were highly frequent
among P. mirabilis isolated from companion animals and humans
(Table 3), nevertheless, ucaA gene was less frequent (Table 3). The
haemolysin HmpA/HmpB genes were present in all tested P. mirabilis
(Table 3).
3.3. Population structure
Thirty-nine clusters and 73 unique pulse-types were detected
(Supplementary Fig. 1). Nine clusters included P. mirabilis from both
CA-human and HA-human UTIs (C2, C3, C8, C10, C13, C24, C26, C28
and C29) with some including highly related (Dice index 90%–100%)
CA-human and HA-human P. mirabilis strains (C2, C10, C13, C24, C26
and C28). It should be noted that some of these strains report to dif-
ferent time-periods and were obtained from unrelated patients.
A high number of clusters (43.6% N=17/39) included P. mirabilis
from companion animals and humans (C2, C3, C6, C13, C14, C15, C16,
C17, C22, C25, C26, C27, C28, C31, C37, C38 and C39). The clonal
relatedness between companion animal and human P. mirabilis varied
between 80–100%. Several companion animal strains included in these
clusters were isolated from different time-periods. Cluster C28 is no-
teworthy since it includes one strain, from a dog, 100% similar to one
CA-human P. mirabilis. Furthermore, one P. mirabilis from a cat (C2) was
also found to be 94.7% and 92.4% similar to one CA-human and HA-
human strain, respectively. Some P. mirabilis strains isolated from dogs
and cats (C21 and C34) also showed high similarity (90%–100%).
Based on veterinary records, only strains FMV5954B/03 and FMV5955/
03 were found to be epidemiologically related, since they were isolated
in the same week from two cats admitted at the same veterinary
practice.
P. mirabilis CMY-2-producer strains from companion animals did not
cluster all together. However, C36 included five P. mirabilis from
companion animals (85.8%–95.7% similarity), of which, four (80%)
were multidrug-resistant CMY-2-producers.
4. Discussion
Currently there are few studies characterizing the clonal population
structure epidemiology of human or companion animal uropathogenic
P. mirabilis strains (Gaastra et al., 1996; Sabbuba et al., 2003; Mathur
et al., 2008). A high number of single pulse-types were detected both in
human and in companion animal P. mirabilis strains in this study.
Nevertheless, several PFGE clusters composed of P. mirabilis isolated in
different years were detected, pointing to a higher dissemination of
some clusters.
P. mirabilis is known to cause nosocomial infections (Armbruster
and Mobley, 2012). The detection of several closely related HA-human
strains likely resulted from nosocomial dissemination. The two identical
P. mirabilis from two cats admitted at the same clinic, may also point to
nosocomial events. Notably, the nine clusters that included P. mirabilis
from CA-human and HA-human UTIs highlight the possible circulation
of some strains between the hospital and community environment.
One previous study conducted on a limited number of P. mirabilis of
several sources, detected one P. mirabilis strain from a dog that was
closely related to one strain from a human (Schultz et al., 2015). In the
present study, a high number of PFGE clusters (43.6%) contained
strains from companion animal and human origin, including some with
significant similarity (90%–100%). Thus, these results point to the
zoonotic potential of uropathogenic P. mirabilis. The close similarity of
some strains from cats and dogs also highlights the possibility of P.
mirabilis transfer between pets.
Overall, HA-human P. mirabilis seemed to have higher antimicrobial
resistance frequencies. However, the fact that this study relied on
convenience samples collected in different time-spans is a study lim-
itation that restricts more extensive comparisons. Another limitation
from this study was the lack of data regarding any prior antimicrobial
treatment to the sampling.
Table 3











mrpA 98.9% (n= 181) 99.1% (n= 106) 98% (n=49) 100% (n=26) 1
pmfA 98.9% (n= 181) 100% (n=107) 96% (n=48) 100% (n=26) 0.1711
ucaA 85.2% (n= 156) 86.9% (n= 93) 80% (n=40) 88.5% (n= 23) 0.5272
Haemolysin
HmpA/HmpB 100% (n=183) 100% (n=107) 100% (n=50) 100% (n=26) 1
Legend: n, number of isolates; HA-human, human hospital-patient UTI; CA-human, human community-acquired UTI; a, P. mirabilis from companion animals were
compared with P. mirabilis from humans (CA-human+HA-human) by Fisher’s Exact test.
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Nonetheless, some of the higher resistance frequencies in this study
were detected against important antimicrobials for UTI treatment, such
as trimethoprim-sulfamethoxazole, fluoroquinolones and beta-lactams.
A previous study from Portugal reported higher antimicrobial re-
sistance frequencies among P. mirabilis from humans with community-
acquired UTI (Costa et al., 2018). Part of the companion animal P.
mirabilis strains here characterized have been included in a previous
study analysing the temporal trends of antimicrobial resistance in UTI
(Marques et al., 2017). It is noteworthy that in this previous study, a
significant increase in MDR P. mirabilis third-generation cephalosporin
resistance was detected due to the presence of CMY-2 beta-lactamase
(Marques et al., 2017).
The P. mirabilis isolated from humans in this study were all third-
generation cephalosporin susceptible. However, the detection of AmpC-
producing P. mirabilis from human infection is being increasingly re-
ported in Europe (D’Andrea et al., 2011; Aogáin et al., 2016). Inter-
estingly, in our study, several MDR CMY-2 producing P. mirabilis strains
from companion animals, including unrelated strains from a wide time-
frame, clustered together. This may point to the expansion of MDR
CMY-2-producing PFGE C36 among companion animals. A previous
study conducted in the UK, using whole genome sequencing (WGS), has
reported the expansion of two clones of CMY-2-producing P. mirabilis in
human infection (Aogáin et al., 2016). Since all CMY-2-producing P.
mirabilis from companion animals from the present study were MDR
and resistant to 5–9 antimicrobial categories, their possible expansion is
worrisome.
Companion animal and human P. mirabilis strains harboured similar
antimicrobial resistance genes except blaCMY-2, sul3, floR and aac(3)-IV,
only detected in companion animals. Therefore, P. mirabilis from com-
panion animals were reservoirs of important resistance genes. The high
dissemination of sul1 and sul2 in P. mirabilis is in line with the high
frequency of these resistance genes in other Enterobacteriaceae from
Portugal (Antunes et al., 2005). The trimethoprim/sulfamethoxazole
non-susceptible strains lacking sul1, sul2 and sul3 may harbour untested
resistance mechanism such as the recently described sul4 (Razavi et al.,
2017). The presence of qnrD among fluoroquinolone-non-susceptible P.
mirabilis agrees with previous published data (Harada et al., 2014;
Jacoby et al., 2014; Schultz et al., 2017a; de Jong et al., 2018).
Nevertheless, the frequency of qnrD detected in P. mirabilis from com-
panion animals in the present study was higher than in previous studies
(Harada et al., 2014; Schultz et al., 2017a). The main acquired fluor-
oquinolone resistance mechanism in Enterobacteriaceae is the acquisi-
tion of mutations on the quinolone resistance-determining regions
(QRDR) (Weigel et al., 2002; Harada et al., 2014). Furthermore, gen-
erally resistance to a given fluoroquinolone is accompanied by elevated
non-wild type MIC values of other fluoroquinolones (Hernández et al.,
2000). It was interesting to notice that several P. mirabilis strains from
the present study did not have clinical cross-resistance to all tested
fluoroquinolones. The higher clinical resistance of P. mirabilis towards
enrofloxacin than to ciprofloxacin was also noted in a previous study
conducted in P. mirabilis of dog origin and several QRDR mutations
were reported (Harada et al., 2014). QRDR mutations of ciprofloxacin-
resistant and levofloxacin-susceptible P. mirabilis strains from humans
have also been reported (Weigel et al., 2002). The temporal change in
fluoroquinolone resistance phenotype in P. mirabilis from companion
animals could be a consequence of antimicrobial use over time. The
characterization of QRDR and determination of fluoroquinolone
minimal inhibitory concentrations should be pursued in the future.
The aphAI-IAB aminoglycoside phosphotransferase has been pre-
viously detected in P. mirabilis through WGS (Di Pilato et al., 2016). To
our knowledge, this is the first detection of aphAI-IAB in P. mirabilis
from companion animals and the first report of its frequency among
clinical relevant P. mirabilis. The detection of floR only in companion
animal strains arguments to different chloramphenicol/florfenicol re-
sistance epidemiology between companion animals and humans. In
Salmonella, the floR is sometimes present in the Salmonella genomic
island 1 (SGI1) (Hall, 2010). Interestingly, some SGI1 variants have
already been described in MDR P. mirabilis from companion animals
and humans (Schultz et al., 2015).
The high frequency of ucaA, mrpA and pmfA fimbriae genes detected
in this study could be expected based on previous phenotypical and
genotypic studies conducted in P. mirabilis from companion animals and
humans, respectively (Bijlsma et al., 1995; Gaastra et al., 1996; Sosa
et al., 2006). The comparison of UCA/NAF, MR/P and PMF fimbrial
adhesins among strains from companion animals and humans in the
future may help to better understand P. mirabilis zoonotic potential.
Although, early phenotypical studies have shown that most P. mirabilis
from dogs with UTI were haemolytic (Gaastra et al., 1996), to our
knowledge, this is the first report of the haemolysin HmpA/HmpB
coding genes presence and frequency among companion animal strains.
The high frequency of HmpA/HmpB in P. mirabilis from humans agrees
with previous results (Cestari et al., 2013).
There is a lack of studies comparing the clonal relatedness between
P. mirabilis from companion animals and humans. Furthermore, the few
existing studies are focused in selected resistant population from several
infection sources (Schultz et al., 2015, 2017b). To our best knowledge,
this is the first study comparing the clonal relatedness of a large number
of P. mirabilis obtained exclusively from humans and companion ani-
mals with UTIs.
In this study, the P. mirabilis clonal relatedness was accessed only by
PFGE analysis and not also by Multi Locus Sequencing Typing because
the latter isn’t available for this bacterial specie. Future studies using
whole genome sequencing could help to overcome this limitation and
further contribute to understand the risk of uropathogenic P. mirabilis
animal-human transfer.
Studies conducted on E. coli, have found that companion animals
and humans may share uropathogenic strains within the same house-
hold (Johnson and Clabots, 2006). Similar studies should be conducted
regarding P. mirabilis to fully evaluate the risk of animal-human transfer
during UTI. Nevertheless, considering the clonal relatedness between P.
mirabilis from companion animals and humans in this study, the role of
companion animals in the dissemination of uropathogenic resistant P.
mirabilis should not be neglected. The route of transfer (human to an-
imal and vice versa) is also unknown and warrants attention in future
studies. The lack of hygiene practices has been pointed as a factor for
dissemination of P. mirabilis (Drzewiecka, 2016) and therefore should
be considered when handling companion animals.
5. Conclusion
This study shows that UTI in companion animals and humans may
be caused by closely related P. mirabilis strains and that P. mirabilis from
both origins have common antimicrobial resistant and virulence genes.
Taken together, these results underline the possible zoonotic nature of
P. mirabilis causing UTIs in companion animals, which has important
public-health implications.
Pending additional research, companion animals might be regarded
as possible sources of uropathogenic P. mirabilis to humans and other
companion animals living in close contact.
Funding
This work was supported by FEDER funds through the Programa
Operacional Factores de Competitividade – COMPETE and by National
funds through the FCT – Fundação para a Ciência e a Tecnologia [UID/
CVT/00276/2013] and by the Joint Programming Initiative on
Antimicrobial Resistance [JPIAMR/0002/2016 (PET-Risk
Consortium)]. Adriana Belas and Cátia Marques hold PhD grant SFRH/
BD/113142/2015 and SFRH/BD/77886/2011, respectively
C. Marques et al. Veterinary Microbiology 228 (2019) 77–82
81
Conflict of interests statement
None of the authors has any financial or personal relationships that




We gratefully acknowledge Molly Freeman, PhD from the Centers
for Disease Control and Prevention, USA, for the help regarding opti-
mization of the Pulse Field Gel Electrophoresis typing of P. mirabilis
strains.
Appendix A. Supplementary data
Supplementary material related to this article can be found, in the
online version, at doi:https://doi.org/10.1016/j.vetmic.2018.10.015.
References
Antunes, P., Machado, J., Sousa, J.C., Peixe, L., 2005. Dissemination of sulfonamide re-
sistance genes (sul1, sul2, and sul3) in Portuguese Salmonella enterica strains and re-
lation with integrons. Antimicrob. Agents Chemother. 49, 836–839.
Aogáin, M.M., Rogers, T.R., Crowley, B., 2016. Identification of emergent blaCMY-2-
carrying Proteus mirabilis lineages by whole-genome sequencing. New Microbes New
Infect. 9, 58–62.
Armbruster, C.E., Mobley, H.L., 2012. Merging mythology and morphology: the multi-
faceted lifestyle of Proteus mirabilis. Nat. Rev. Microbiol. 10, 743–754.
Bijlsma, I.G., van Dijk, L., Kusters, J.G., Gaastra, W., 1995. Nucleotide sequences of two
fimbrial major subunit genes, pmpA and ucaA, from canine-uropathogenic Proteus
mirabilis strains. Microbiology 141, 1349–1357.
Cavaco, L.M., Hasman, H., Xia, S., Aarestrup, F.M., 2009. qnrD, a novel gene conferring
transferable quinolone resistance in Salmonella enterica Serovar Kentucky and
Bovismorbificans strains of human origin. Antimicrob. Agents Chemother. 53,
603–608.
Cestari, S.E., Ludovico, M.S., Martins, F.H., da Rocha, S.P., Elias, W.P., Pelayo, J.S., 2013.
Molecular detection of HpmA and HlyA hemolysin of uropathogenic Proteus mirabilis.
Curr. Microbiol. 67, 703–707.
CLSI, 2017. Performance Standards for Antimicrobial Susceptibility Testing. CLSI
Supplement M100S-S27, 26th ed. Clinical and Laboratory Standards Institute,
Wayne, PA, USA 2017.
CLSI, 2018. Performance Standards for Antimicrobial Disk and Dilution Susceptibility
Tests for Bacteria Isolated From Animals. CLSI Supplement VET08, 4th ed. Clinical
and Laboratory Standards Institute, Wayne, PA, USA 2018.
Costa, T., Linhares, I., Ferreira, R., Neves, J., Almeida, A., 2018. Frequency and antibiotic
resistance of bacteria implicated in community urinary tract infections in North
Aveiro between 2011 and 2014. Microb. Drug Resist. 24, 493–504.
de Jong, A., Muggeo, A., El Garch, F., Moyaert, H., de Champs, C., Guillard, T., 2018.
Characterization of quinolone resistance mechanisms in Enterobacteriaceae isolated
from companion animals in Europe (ComPath II study). Vet. Microbiol. 216,
159–167.
D’Andrea, M.M., Literacka, E., Zioga, A., Giani, T., Baraniak, A., Fiett, J., Sadowy, E.,
Tassios, P.T., Rossolini, G.M., Gniadkowski, M., Miriagou, V., 2011. Evolution and
spread of a multidrug-resistant Proteus mirabilis clone with chromosomal AmpC-type
cephalosporinases in Europe. Antimicrob. Agents Chemother. 55, 2735–2742.
Di Pilato, V., Chiarelli, A., Boinett, C.J., Riccobono, E., Harris, S.R., D’Andrea, M.M.,
Thomson, N.R., Rossolini, G.M., Giani, T., 2016. Complete genome sequence of the
first KPC-type carbapenemase-positive Proteus mirabilis strain from a bloodstream
infection. Genome Announc. 4 e00607-16.
Drzewiecka, D., 2016. Significance and roles of Proteus spp. bacteria in natural environ-
ments. Microb. Ecol. 72, 741–758.
Frana, T.S., Carlson, S.A., Griffith, R.W., 2001. Relative distribution and conservation of
genes encoding aminoglycoside-modifying enzymes in Salmonella enterica Serotype
Typhimurium phage type DT104. Appl. Environ. Microbiol. 67, 445–448.
Gaastra, W., van Oosterom, R.A., Pieters, E.W., Bergmans, H.E., van Dijk, L., Agnes, A., ter
Huurne, H.M., 1996. Isolation and characterisation of dog uropathogenic Proteus
mirabilis strains. Vet. Microbiol. 48, 57–71.
Guerra, B., Soto, S.M., Argüelles, J.M., Mendoza, M.C., 2001. Multidrug resistance is
mediated by large plasmids carrying a Class 1 integron in the emergent Salmonella
enterica Serotype [4,5,12:i:−]. Antimicrob. Agents Chemother. 45, 1305–1308.
Hall, R.M., 2010. Salmonella genomic islands and antibiotic resistance in Salmonella
enterica. Future Microbiol. 5, 1525–1538.
Harada, K., Niina, A., Shimizu, T., Mukai, Y., Kuwajima, K., Miyamoto, T., Kataoka, Y.,
2014. Phenotypic and molecular characterization of antimicrobial resistance in
Proteus mirabilis isolates from dogs. J. Med. Microbiol. 63, 1561–1567.
Hernández, J.R., Martínez-Martínez, L., Pascual, A., Suárez, A.I., Perea, E.J., 2000. Trends
in the susceptibilities of Proteus mirabilis isolates to quinolones. J. Antimicrob.
Chemother. 45, 407–408.
Jacoby, G.A., Strahilevitz, J., Hooper, D.C., 2014. Plasmid-mediated quinolone resistance.
Microbiol. Spectr. 2. https://doi.org/10.1128/microbiolspec.PLAS-0006-2013.
Johnson, J.R., Clabots, C., 2006. Sharing of virulent Escherichia coli clones among
household members of a woman with acute cystitis. Clin. Infect. Dis. 43, e101–e108.
Magiorakos, A.P., Srinivasan, A., Carey, R.B., Carmeli, Y., Falagas, M.E., Giske, C.G.,
Harbarth, S., Hindler, J.F., Kahlmeter, G., Olsson-Liljequist, B., Paterson, D.L., Rice,
L.B., Stelling, J., Struelens, M.J., Vatopoulos, A., Weber, J.T., Monnet, D.L., 2012.
Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteria: an
international expert proposal for interim standard definitions for acquired resistance.
Clin. Microbiol. Infect. 18, 268–281.
Marques, C., Belas, A., Franco, A., Aboim, C., Gama, L.T., Pomba, C., 2017. Increase in
antimicrobial resistance and emergence of major international high-risk clonal
lineages in dogs and cats with urinary tract infection: 16 year retrospective study. J.
Antimicrob. Chemother. 73, 377–384.
Mathur, S., Sabbuba, N.A., Suller, M.T., Stickler, D.J., Feneley, R.C., 2008. Genotyping of
urinary and fecal Proteus mirabilis isolates from individuals with long-term urinary
catheters. Eur. J. Clin. Microbiol. Infect. Dis. 24, 643–644.
Maynard, C., Fairbrother, J.M., Bekal, S., Sanschagrin, F., Levesque, R.C., Brousseau, R.,
Masson, L., Larivière, S., Harel, J., 2003. Antimicrobial resistance genes in en-
terotoxigenic Escherichia coli O149:K91 isolates obtained over a 23-year period from
pigs. Antimicrob. Agents Chemother. 47, 3214–3221.
Moyaert, H., Morrissey, I., de Jong, A., El Garch, F., Klein, U., Ludwig, C., Thiry, J.,
Youala, M., 2017. Antimicrobial susceptibility monitoring of bacterial pathogens
isolated from urinary tract infections in dogs and cats across Europe: ComPath re-
sults. Microb. Drug Resist. 23, 391–403.
Perreten, V., Boerlin, P., 2003. A new sulfonamide resistance gene (sul3) in Escherichia coli
is widespread in the pig population of Switzerland. Antimicrob. Agents Chemother.
47, 1169–1172.
Pomba, C., Mendonça, N., Costa, M., Louro, D., Baptista, B., Ferreira, M., Correia, J.D.,
Caniça, M., 2006. Improved multiplex PCR method for the rapid detection of beta-
lactamase genes in Escherichia coli of animal origin. Diagn. Microbiol. Infect. Dis. 56,
103–106.
Pomba, C., Rantala, M., Greko, C., Baptiste, K.E., Catry, B., van Duijkeren, E., Mateus, A.,
Moreno, M.A., Pyörälä, S., Ružauskas, M., Sanders, P., Teale, C., Threlfall, E.J.,
Kunsagi, Z., Torren-Edo, J., Jukes, H., Törneke, K., 2017. Public health risk of anti-
microbial resistance transfer from companion animals. J. Antimicrob. Chemother. 72,
957–968.
Razavi, M., Marathe, N.P., Gillings, M.R., Flach, C.F., Kristiansson, E., Joakim Larsson,
D.G., 2017. Discovery of the fourth mobile sulfonamide resistance gene. Microbiome
5, 160.
Robicsek, A., Strahilevitz, J., Jacoby, G.A., Macielag, M., Abbanat, D., Park, C.H., Bush,
K., Hooper, D.C., 2006a. Fluoroquinolone-modifying enzyme: a new adaptation of a
common aminoglycoside acetyltransferase. Nat. Med. 12, 83–88.
Robicsek, A., Strahilevitz, J., Sahm, D.F., Jacoby, G.A., Hooper, D.C., 2006b. qnrpreva-
lence in ceftazidime-resistant Enterobacteriaceae isolates from the United States.
Antimicrob. Agents Chemother. 50, 2872–2874.
Sabbuba, N.A., Mahenthiralingam, E., Stickler, D.J., 2003. Molecular epidemiology of
Proteus mirabilis infections of the catheterized urinary tract. J. Clin. Microbiol. 41,
4961–4965.
Schultz, E., Baucheron, S., Lupo, A., Saras, E., Cloeckaert, A., Doublet, B., Madec, J.Y.,
Haenni, M., 2017a. Complete sequences of qnrD-carrying plasmids inProteus spp.
collected from French animals. J. Glob. Antimicrob. Resist. 10, 306–307.
Schultz, E., Cloeckaert, A., Doublet, B., Madec, J.-Y., Haenni, M., 2017b. Detection of
SGI1/PGI1 elements and resistance to extended-spectrum cephalosporins in Proteae
of animal origin in France. Front. Microbiol. 8, 32.
Schultz, E., Haenni, M., Mereghetti, L., Siebor, E., Neuwirth, C., Madec, J.Y., Cloeckaert,
A., Doublet, B., 2015. Survey of multidrug resistance integrative mobilizable ele-
ments SGI1 and PGI1 in Proteus mirabilis in humans and dogs in France, 2010-13. J.
Antimicrob. Chemother. 70, 2543–2546.
Sáenz, Y., Briñas, L., Domínguez, E., Ruiz, J., Zarazaga, M., Vila, J., Torres, C., 2004.
Mechanisms of resistance in multiple-antibiotic-resistant Escherichia coli strains of
human, animal, and food origins. Antimicrob. Agents Chemother. 48, 3996–4001.
SFM, 2010. Comité de l’antibiogramme de la Société Française de Microbiologie:
Recommandations 2010. Société Française de Microbiologie, Paris, France.
Sosa, V., Schlapp, G., Zunino, P., 2006. Proteus mirabilis isolates of different origins do not
show correlation with virulence attributes and can colonize the urinary tract of mice.
Microbiology 152, 2149–2157.
Wang, M., Guo, Q., Xu, X., Wang, X., Ye, X., Wu, S., Hooper, D.C., Wang, M., 2009. New
plasmid-mediated quinolone resistance gene, qnrC, found in a clinical isolate of
Proteus mirabilis. Antimicrob. Agents Chemother. 53, 1892–1897.
Weigel, L.M., Anderson, G.J., Tenover, F.C., 2002. DNA gyrase and topoisomerase IV
mutations associated with fluoroquinolone resistance in Proteus mirabilis.
Antimicrob. Agents Chemother. 46, 2582–2587.
C. Marques et al. Veterinary Microbiology 228 (2019) 77–82
82
